Services Updated at Creative Biolabs to Advance Complement Antibody Development

Recently, much potential has been seen in the application of complement antibodies to the treatment of complement-related diseases due to the central role of complement therapy in innate immunity, which has encouraged a significant number of studies devoted to complement therapy to be conducted by global researchers in this field. Huge progress has been made in complement antibody development. Ranked as one of the top biotech companies, Creative Biolabs is committed to providing diverse services to support and advance therapeutic antibody development, including C5 drug development services, CD20 drug development services, and other therapeutic antibody development services.

“Complement C5 has a key role in inflammatory and cell killing processes,” according to a scientist at Creative Biolabs, “and current drug research has a major focus on anti-C5 antibodies, which are considered a promising treatment strategy.”

With years of experience and firm determination, Creative Biolabs remains contributing to the development of antibodies targeting the complement C5 based on advanced development platforms, especially monoclonal antibodies, due to their promising scientific applications.

Besides, successful applications of anti-CD20 monoclonal antibodies in various B cell disorders have also attracted much attention from researchers worldwide over the past several years.

“Research regarding various applications of anti-CD20 antibodies in disease spikes up,” added the scientist, “and our scientists are committed to providing novel and custom CD20 antibody development services covering various species to meet the research requirements of customers.”

Scientists at Creative Biolabs established multiple drug development platforms to assist in various projects, promoting the development of drugs targeting CD20 and C5. Platform functions include drug design, screening, and analysis to meet the diverse demands of customers’ programs. For years, Creative Biolabs has completed hundreds of complement drug development projects and accumulated extensive experience in this field. It is worth considering Creative Biolabs as the first choice when in need of drug development support.

To learn more about services related to complement antibody development at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs, a biotech CRO based in the US, has established its complement therapeutic system and is confident in providing global customers with top-notch therapeutic antibody development services to achieve significant advancements in their research programs, ranging from C5 antibody development to CD59 (MIRL) antibody development to meet customers’ specific needs.

Media Contact

Company Name
Creative Biolabs
Contact Name
Candy Swift
New York
United States

comtex tracking


You may also like...